Searchable abstracts of presentations at key conferences in endocrinology

ea0003p225 | Reproduction | BES2002

Oral clatharate-DHEA as a potential form of androgen replacement in hypogonadal men. A phase 2, open label, placebo controlled, parallel group pharmacokinetic study

Oxynos C , Phillips J , Laing I , Saad F , Wu F

BACKGROUND: DHEA and DHEAS, can be converted into Androstenedione, T and DHT as well as oestrogens by peripheral tissues. In normal men the conversion rate of IV-infused radiolabelled DHEAS to T is only 0.7%. In hypogonadal men, this conversion rate may be increased. We hypothesise that a pharmacological dose of orally administered DHEA may be able to raise plasma T into the normal range in hypogonadal men. METHODS: Local Ethical Committee Approval was obtained. Two groups (n=...

ea0022s1.1 | European networks | ECE2010

Endocrinology of the aging male: the European Male Ageing Study (EMAS)

Wu F

The relationships between alterations in hormones with the clinical features of senescence remain unclear in ageing men. We have investigated the natural history of and risk factors for potential adverse consequences associated with low testosterone in the European Male Ageing Study (EMAS), a population-based prospective cohort study of 3369 men (aged 40–79 years) from the general population of 8 European countries. A wide variety of clinical variables pertinent to genera...

ea0011s43 | Controversies in male health | ECE2006

Cardiovascular effects of androgens

Wu F

The burgeoning interest in treating androgen deficiency against the background of the age-related decline in circulating testosterone in middle-aged and elderly men has outpaced the accrual of an adequate evidence base on causation, natural history, and accuracy/validity of diagnosis. The relevance of age-related hormonal changes in the somatotrohic and adrenal axes are currently also unclear. Fuelled by the increased choice of androgen preparations and heightened patient expe...

ea0008s20 | Consequences of a lack of androgens | SFE2004

Hormonal Male Contraception: An Update

Wu F

Maintenance of spermatogenesis depends on adequate gonadotrophin and intratesticular testosterone concentrations. Hormonal contraception for men interrupts this physiological axis by various means of gonadotrophin suppression; this induces reversible azoospermia or severe oligozoospermia in virtually all men. Clinical trials have confirmed that high contraceptive efficacy, similar to female hormonal contraceptives, can be reliably attained with few side effects. However, the s...

ea0007p177 | Reproduction | BES2004

Oral tibolone combined with testosterone as a potential male contraceptive: pharmacodynamic study examining additive effects in suppression of pituitary-testicular axis

Oxynos C , Wu F

BACKGROUND: Hormonal male contraception is based on the reversible suppression of LH and FSH resulting in intratesticular testosterone depletion with subsequent spermatogenic arrest and infertility. Tibolone, a unique synthetic steroid with mixed progestational, androgenic and oestrogenic activities, has been shown to suppress gonadotrophins, inhibit ovulation and postmenopausal hot flushes in women. HYPOTHESIS: We hypothesise that the hybrid anti-gonadotrophic action of Tibol...

ea0007p187 | Reproduction | BES2004

Effects of oral nomegestrol acetate, a 19 norprogesterone-derived progestin on the reproductive axis and lipids in men

Hay C , Wu F

Objectives: To assess the gonadotrophin suppressive effects of 2 doses of nomegestrol acetate (NOMA) alone and in combination with testosterone enanthate (TE) in men.To evaluate the potential effects of NOMA on circulating lipids in menMethods: Twelve healthy male volunteers were recruited. Subjects were randomly allocated to receive either NOMA 5 milligrams or NOMA 10 milligrams orally daily. Study duration included 28 days treatm...

ea0007p192 | Reproduction | BES2004

Intramuscular testosterone (T) undecanoate for the treatment of male hypogonadism: a parallel-group randomised open-label pharmacokinetic study

Hay C , Wu F

Objective: To identify the optimal regime for physiological replacement in hypogonadism. We assessed the pharmacokinetics of 3 different dose-intervals for i.m. administration of the new parenteral formulation of testosterone undecanoate in castor oil (Schering AG Berlin).Methods: Ten hypogonadal subjects (primary n equals 4 or secondary n equals 6) with a baseline T at diagnosis of less than 7 nanomols per litre were recruited and randomly allocated int...

ea0029oc14.3 | Male Reproduction | ICEECE2012

Comparison of serum testosterone and estradiol levels in 3174 European men as measured by a platform immunoassay and mass spectrometry; relevance for the diagnostics in aging men

Huhtaniemi I. , Tajar A. , Wu F.

Testosterone (T) and estradiol (E2) are the two most important sex steroids in men and women, respectively, and their accurate determination in serum is of crucial importance in assessing gonadal function both in clinical management and research. The limitations of serum T and E2 measurements using non-extraction platform immunoassays (IA) are widely recognized. Switching to more specific mass spectrometry (MS)-based methods has been advocated but directly comparative data on ...